TY - JOUR
T1 - Intramuscular Pentamidine for the Prevention of Pneumocystis carinii Pneumonia in Patients Infected with Human Immunodeficiency Virus
AU - Cheung, Tony W.
AU - Matta, Ray
AU - Neibart, Eric
AU - Hammer, Glenn
AU - Chusid, Eileen
AU - Sacks, Henry S.
AU - Szabo, Susan
AU - Rose, David
N1 - Funding Information:
Received 30 March 1992; revised 16 June 1992. This work was presented in part at the 7th International Conference on AIDS held on 17-21 June 1991 in Florence. Italy. Grant Support: This work was supported in part by the National Institute ofAllergyand InfectiousDiseases(VaI-AI27667). Reprints or correspondence: Dr. Tony W. Cheung, Division ofInfectious Diseases, Mount Sinai Medical Center, New York, New York 10029.
PY - 1993/1/1
Y1 - 1993/1/1
N2 - We retrospectively reviewed the charts of 96 patients infected with human immunodeficiency virus (HIV) who received intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia (PCP). These patients, all of whom had either a history of PCP or a CD4lymphocyte count of ⩽0.2 × 109/L, were intolerant of sulfa drugs, neutropenic, or intolerant of aerosolized treatment. Intramuscular pentamidine was given monthly by the Z-track technique at a dosage of 300 mg (4 mg/kg if the patient weighed <50 kg). During a total of 350 months of primary prophylaxis in 47 patients and 426 months of secondary prophylaxis in 49 patients, only three cases of PCP occurred. More than 73% of the patients were receiving zidovudine concomitantly. Adverse reactions to intramuscular pentamidine included two episodes of hypotension, three of sterile abscess, two of glucose intolerance, and one of asymptomatic hypoglycemia. The administration of intramuscular pentamidine by the Z-track technique for PCP prophylaxis appears to be highly effective and minimally toxic.
AB - We retrospectively reviewed the charts of 96 patients infected with human immunodeficiency virus (HIV) who received intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia (PCP). These patients, all of whom had either a history of PCP or a CD4lymphocyte count of ⩽0.2 × 109/L, were intolerant of sulfa drugs, neutropenic, or intolerant of aerosolized treatment. Intramuscular pentamidine was given monthly by the Z-track technique at a dosage of 300 mg (4 mg/kg if the patient weighed <50 kg). During a total of 350 months of primary prophylaxis in 47 patients and 426 months of secondary prophylaxis in 49 patients, only three cases of PCP occurred. More than 73% of the patients were receiving zidovudine concomitantly. Adverse reactions to intramuscular pentamidine included two episodes of hypotension, three of sterile abscess, two of glucose intolerance, and one of asymptomatic hypoglycemia. The administration of intramuscular pentamidine by the Z-track technique for PCP prophylaxis appears to be highly effective and minimally toxic.
UR - http://www.scopus.com/inward/record.url?scp=0027507250&partnerID=8YFLogxK
U2 - 10.1093/clinids/16.1.22
DO - 10.1093/clinids/16.1.22
M3 - Article
C2 - 8448314
AN - SCOPUS:0027507250
SN - 1058-4838
VL - 16
SP - 22
EP - 25
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 1
ER -